hers glp-1 Novo Nordisk Forms Partnership with Hims & Hers Is Making Popular GLP-1

Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3)

Ongoing and future largescale randomized trials will be critical for clarifying efficacy and safety for this use

Each has its own benefits, and your provider can help you understand which might align best with your needs and lifestyle

Research Background & Mechanistic Focus Current research use centers on single-pathway incretin receptor signaling and comparative peptide-pathway models, comparative presentation or formulation behavior where applicable, and controlled experimental models designed to evaluate compound-specific signaling activity within non-clinical laboratory systems